PURPOSE: Flavopiridol is a cyclin-dependent kinase inhibitor with preclinical activity against prostate cancer cell lines. A Phase II trial was conducted to determine the activity of flavopiridol in patients with metastatic hormone-refractory prostate cancer. EXPERIMENTAL DESIGN: A total of 36 patients was enrolled from several institutions and treated with a 72-h continuous infusion of flavopiridol every 14 days at the eventual starting dose of 40 mg/m(2)/day. Dose escalation up to 60 mg/m(2)/day was permitted if no significant toxicity was observed. Responses were assessed every 12 weeks. Only those patients completing four courses of the 72-h infusion were considered evaluable for response because the primary objective was to determine progression-free survival at 6 months given the cytostatic nature of the agent. RESULTS: This study was conducted in a two-stage fashion. During the first stage, at least 20 evaluable patients needed to be enrolled to assess response. There were 22 of 36 patients evaluable for response. No objective responses were observed. Only 4 patients had stable disease for 16, 26, 29, and 48 weeks, respectively, stopping the trial by design as only 3 of 22 (14%) of the patients met the 6-month progression-free survival end point. The most common toxicities were diarrhea (grade 1 and 2) and nausea, although some grade 3 and 4 diarrhea (11 and 6%, respectively) were evident. CONCLUSIONS: Flavopiridol has disappointing single-agent activity in hormone-refractory prostate cancer when administered at this dose and schedule. Its use in prostate cancer should be reserved for evaluation in combination therapies or alternative schedules.
PURPOSE:Flavopiridol is a cyclin-dependent kinase inhibitor with preclinical activity against prostate cancer cell lines. A Phase II trial was conducted to determine the activity of flavopiridol in patients with metastatic hormone-refractory prostate cancer. EXPERIMENTAL DESIGN: A total of 36 patients was enrolled from several institutions and treated with a 72-h continuous infusion of flavopiridol every 14 days at the eventual starting dose of 40 mg/m(2)/day. Dose escalation up to 60 mg/m(2)/day was permitted if no significant toxicity was observed. Responses were assessed every 12 weeks. Only those patients completing four courses of the 72-h infusion were considered evaluable for response because the primary objective was to determine progression-free survival at 6 months given the cytostatic nature of the agent. RESULTS: This study was conducted in a two-stage fashion. During the first stage, at least 20 evaluable patients needed to be enrolled to assess response. There were 22 of 36 patients evaluable for response. No objective responses were observed. Only 4 patients had stable disease for 16, 26, 29, and 48 weeks, respectively, stopping the trial by design as only 3 of 22 (14%) of the patients met the 6-month progression-free survival end point. The most common toxicities were diarrhea (grade 1 and 2) and nausea, although some grade 3 and 4 diarrhea (11 and 6%, respectively) were evident. CONCLUSIONS:Flavopiridol has disappointing single-agent activity in hormone-refractory prostate cancer when administered at this dose and schedule. Its use in prostate cancer should be reserved for evaluation in combination therapies or alternative schedules.
Authors: Vicki Gordon; Shriti Bhadel; Winfried Wunderlich; JoAnn Zhang; Scott B Ficarro; Sahana A Mollah; Jeffrey Shabanowitz; Donald F Hunt; Ioannis Xenarios; William C Hahn; Mark Conaway; Michael F Carey; Daniel Gioeli Journal: Mol Endocrinol Date: 2010-10-27
Authors: Bhuvaneswari Ramaswamy; Mitch A Phelps; Robert Baiocchi; Tanios Bekaii-Saab; Wenjun Ni; Ju-Ping Lai; Anna Wolfson; Mark E Lustberg; Lai Wei; Deidre Wilkins; Angela Campbell; Daria Arbogast; Austin Doyle; John C Byrd; Michael R Grever; Manisha H Shah Journal: Invest New Drugs Date: 2010-10-12 Impact factor: 3.850
Authors: John C Byrd; Thomas S Lin; James T Dalton; Di Wu; Mitch A Phelps; Beth Fischer; Mollie Moran; Kristie A Blum; Brad Rovin; Michelle Brooker-McEldowney; Sarah Broering; Larry J Schaaf; Amy J Johnson; David M Lucas; Nyla A Heerema; Gerard Lozanski; Donn C Young; Jose-Ramon Suarez; A Dimitrios Colevas; Michael R Grever Journal: Blood Date: 2006-09-26 Impact factor: 22.113
Authors: N Nitta; A Sonoda; A Seko; S Ohta; Y Nagatani; K Tsuchiya; H Otani; T Tanaka; S Kanasaki; M Takahashi; K Murata Journal: Br J Radiol Date: 2009-12-17 Impact factor: 3.039
Authors: Xiaojuan Yang; Xiaobin Zhao; Mitch A Phelps; Longzhu Piao; Darlene M Rozewski; Qing Liu; L James Lee; Guido Marcucci; Michael R Grever; John C Byrd; James T Dalton; Robert J Lee Journal: Int J Pharm Date: 2008-08-20 Impact factor: 5.875
Authors: Jia Ji; Diane R Mould; Kristie A Blum; Amy S Ruppert; Ming Poi; Yuan Zhao; Amy J Johnson; John C Byrd; Michael R Grever; Mitch A Phelps Journal: Clin Cancer Res Date: 2013-01-08 Impact factor: 12.531